Literature DB >> 16254546

The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults.

Jennifer E Cameron1, Donald Mercante, Megan O'Brien, Ann M Gaffga, Janet E Leigh, Paul L Fidel, Michael E Hagensee.   

Abstract

BACKGROUND: Prevalence of human papillomavirus (HPV)-associated oral condylomas has reportedly increased in HIV-infected individuals since the introduction of highly active antiretroviral therapy (HAART). The relationships between HIV therapy regimen, overall health, and subclinical oral HPV have not been examined. GOAL: To determine oral HPV genotype prevalence and the impact of HAART and health in the HIV+ population. STUDY: An L1 consensus-primer polymerase chain reaction and linear array assay were used to examine the prevalence of 27 HPV genotypes in saliva of 98 HIV+ individuals. Risk assessment variables were compared to oral HPV status.
RESULTS: Oral HPV was detected in 37% of HIV+ African American individuals. Caucasians were at greater risk of oral HPV infection than African Americans. Markers of advanced HIV disease did not predict HPV status. Therapy status was associated with HPV detection.
CONCLUSIONS: Treatment of HIV, rather than HIV immunosuppression, appears to play a role in oral HPV infections in HIV+ individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254546     DOI: 10.1097/01.olq.0000175398.34610.2e

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  28 in total

1.  The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

Authors:  M Israr; D Mitchell; S Alam; D Dinello; J J Kishel; C Meyers
Journal:  HIV Med       Date:  2010-08-15       Impact factor: 3.180

Review 2.  The rising challenge of non-AIDS-defining cancers in HIV-infected patients.

Authors:  John F Deeken; Angelique Tjen-A-Looi; Michelle A Rudek; Catherine Okuliar; Mary Young; Richard F Little; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2012-07-09       Impact factor: 9.079

3.  Recalcitrant oral squamous cell papilloma lesions in two HIV-infected patients successfully treated with topical imiquimod.

Authors:  Lilly Esquivel-Pedraza; Laura Fernández-Cuevas; Marcela Saeb-Lima; Brenda Alicia Guerrero-Ramos; Amparo Hernández-Salazar; Silvia Méndez-Flores
Journal:  J Dermatol Case Rep       Date:  2015-03-31

Review 4.  [Human papilloma virus-induced disease in HIV-positive patients].

Authors:  R Wienecke; N H Brockmeyer; A Kreuter
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

5.  Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.

Authors:  Mohd Israr; Danielle Mitchell; Samina Alam; Donald Dinello; Joseph J Kishel; Craig Meyers
Journal:  Antivir Ther       Date:  2010

Review 6.  Overview of the oral HIV/AIDS Research Alliance Program.

Authors:  C H Shiboski; J Y Webster-Cyriaque; M Ghannoum; J S Greenspan; D Dittmer
Journal:  Adv Dent Res       Date:  2011-04

Review 7.  The interaction between human papillomavirus and other viruses.

Authors:  J T Guidry; R S Scott
Journal:  Virus Res       Date:  2016-11-05       Impact factor: 3.303

8.  Epidemiology of head and neck squamous cell cancer among HIV-infected patients.

Authors:  Gypsyamber Dʼsouza; Thomas E Carey; William N William; Minh Ly Nguyen; Eric C Ko; James Riddell; Sara I Pai; Vishal Gupta; Heather M Walline; J Jack Lee; Gregory T Wolf; Dong M Shin; Jennifer R Grandis; Robert L Ferris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

Review 9.  Oral complications of HIV disease.

Authors:  Jair C Leao; Camila M B Ribeiro; Alessandra A T Carvalho; Cristina Frezzini; Stephen Porter
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

10.  Epithelial maturation and molecular biology of oral HPV.

Authors:  Liviu Feller; Razia Ag Khammissa; Neil H Wood; Johan Lemmer
Journal:  Infect Agent Cancer       Date:  2009-11-25       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.